Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $32 and keeps an Overweight rating on the shares. The firm notes Beta reported Q1 results that beat nicely across the board. Management also raised guidance for the year across many key metrics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX: